Amylou Dueck, PhD
@biostatgirl.bsky.social
Oncology & Patient-Reported Outcomes Biostatistician looking for a new social media home. I love bar charts too. Opinions are my own.
https://duecklab.github.io
https://duecklab.github.io
Reposted by Amylou Dueck, PhD
Our CRTI group PROs and Poop! 💩 (intersection of patient-reported outcomes and fecal microbiome) #ASHCRTI cc @ash.hematology.org @biostatgirl.bsky.social
August 5, 2025 at 10:45 PM
Our CRTI group PROs and Poop! 💩 (intersection of patient-reported outcomes and fecal microbiome) #ASHCRTI cc @ash.hematology.org @biostatgirl.bsky.social
Reposted by Amylou Dueck, PhD
Currently at #EHA2025: @broeckelmann.bsky.social presenting our recent @thelancethaem.bsky.social commission on adverse events, starting with our paper (with @biostatgirl.bsky.social) on advancing the measurement & dissemination of AE data HT @eddiecliff.bsky.social #EHA25
June 13, 2025 at 1:36 PM
Currently at #EHA2025: @broeckelmann.bsky.social presenting our recent @thelancethaem.bsky.social commission on adverse events, starting with our paper (with @biostatgirl.bsky.social) on advancing the measurement & dissemination of AE data HT @eddiecliff.bsky.social #EHA25
Reposted by Amylou Dueck, PhD
If you want to hear more from the authors of the first set of commission manuscripts, our @thelancethaem.bsky.social podcast is now online! www.buzzsprout.com/1564352/epis... ft @biostatgirl.bsky.social @broeckelmann.bsky.social #EHA2025 #EHA25
June 13, 2025 at 1:48 PM
If you want to hear more from the authors of the first set of commission manuscripts, our @thelancethaem.bsky.social podcast is now online! www.buzzsprout.com/1564352/epis... ft @biostatgirl.bsky.social @broeckelmann.bsky.social #EHA2025 #EHA25
Presenting a #patientreportedoutcomes workshop at Society for Clinical Trials 46th Annual Meeting! #SCT2025 #clinicaltrials #PROs @christinayap.bsky.social
May 18, 2025 at 10:29 PM
Presenting a #patientreportedoutcomes workshop at Society for Clinical Trials 46th Annual Meeting! #SCT2025 #clinicaltrials #PROs @christinayap.bsky.social
Reposted by Amylou Dueck, PhD
Implementation of Symptom Monitoring With Electronic Patient-Reported Outcomes: Perspectives and Recommendations From Community Oncology Practices (Alliance AFT-39).
ascopubs.org/doi/10.1200/...
@pallonccop.bsky.social
#PallOnc #CancerCare
@ethanbasch.bsky.social
@biostatgirl.bsky.social
ascopubs.org/doi/10.1200/...
@pallonccop.bsky.social
#PallOnc #CancerCare
@ethanbasch.bsky.social
@biostatgirl.bsky.social
April 12, 2025 at 1:02 AM
Implementation of Symptom Monitoring With Electronic Patient-Reported Outcomes: Perspectives and Recommendations From Community Oncology Practices (Alliance AFT-39).
ascopubs.org/doi/10.1200/...
@pallonccop.bsky.social
#PallOnc #CancerCare
@ethanbasch.bsky.social
@biostatgirl.bsky.social
ascopubs.org/doi/10.1200/...
@pallonccop.bsky.social
#PallOnc #CancerCare
@ethanbasch.bsky.social
@biostatgirl.bsky.social
What an incredible week in Casablanca, Morocco, for @ash.hematology.org Clinical Research Training Institute & Training Day, Mediterranean, Middle East, and Northern Africa. I’m so inspired by the growth of the trainees this week & I’m excited to see the future #hematology leaders they become! #CRTI
April 5, 2025 at 12:25 PM
What an incredible week in Casablanca, Morocco, for @ash.hematology.org Clinical Research Training Institute & Training Day, Mediterranean, Middle East, and Northern Africa. I’m so inspired by the growth of the trainees this week & I’m excited to see the future #hematology leaders they become! #CRTI
Reposted by Amylou Dueck, PhD
PRO-TECT trial of ePROs final results @biostatgirl.bsky.social
- 52 onc practices, randomized to weekly ePRO symptom surveys vs usual care
- no difference in OS
- 6% reduction in ER visits
- delayed deterioration of HRQOL w/ ePROs
Important for patients & health care system. #oncsky
buff.ly/3Xi7cen
- 52 onc practices, randomized to weekly ePRO symptom surveys vs usual care
- no difference in OS
- 6% reduction in ER visits
- delayed deterioration of HRQOL w/ ePROs
Important for patients & health care system. #oncsky
buff.ly/3Xi7cen
February 25, 2025 at 3:42 PM
PRO-TECT trial of ePROs final results @biostatgirl.bsky.social
- 52 onc practices, randomized to weekly ePRO symptom surveys vs usual care
- no difference in OS
- 6% reduction in ER visits
- delayed deterioration of HRQOL w/ ePROs
Important for patients & health care system. #oncsky
buff.ly/3Xi7cen
- 52 onc practices, randomized to weekly ePRO symptom surveys vs usual care
- no difference in OS
- 6% reduction in ER visits
- delayed deterioration of HRQOL w/ ePROs
Important for patients & health care system. #oncsky
buff.ly/3Xi7cen
Reposted by Amylou Dueck, PhD
🚨Heme #MedEd enthusiasts!🚨
Want to level⬆️ heme education skills? 🩸ASH MEI is accepting applications!
✅ Expert yr-long mentoring
✅ Develop leaders in heme MedEd scholarship
✅ Community of like-minded educators
It was game-changer in my career- as participant, now faculty & co-director! Join us!
Want to level⬆️ heme education skills? 🩸ASH MEI is accepting applications!
✅ Expert yr-long mentoring
✅ Develop leaders in heme MedEd scholarship
✅ Community of like-minded educators
It was game-changer in my career- as participant, now faculty & co-director! Join us!
February 19, 2025 at 12:04 AM
🚨Heme #MedEd enthusiasts!🚨
Want to level⬆️ heme education skills? 🩸ASH MEI is accepting applications!
✅ Expert yr-long mentoring
✅ Develop leaders in heme MedEd scholarship
✅ Community of like-minded educators
It was game-changer in my career- as participant, now faculty & co-director! Join us!
Want to level⬆️ heme education skills? 🩸ASH MEI is accepting applications!
✅ Expert yr-long mentoring
✅ Develop leaders in heme MedEd scholarship
✅ Community of like-minded educators
It was game-changer in my career- as participant, now faculty & co-director! Join us!
Reposted by Amylou Dueck, PhD
Our invited review on how to integrate patient-reported outcomes into hematology clinical trials to measure treatment tolerability. Many thanks to Drs. Thanarajasingam and @biostatgirl.bsky.social for your collaboration! #medsky #lymsm #leusm #mmsm pubmed.ncbi.nlm.nih.gov/39198102/
February 17, 2025 at 3:13 PM
Our invited review on how to integrate patient-reported outcomes into hematology clinical trials to measure treatment tolerability. Many thanks to Drs. Thanarajasingam and @biostatgirl.bsky.social for your collaboration! #medsky #lymsm #leusm #mmsm pubmed.ncbi.nlm.nih.gov/39198102/
Onsite retreat today - my fellow biostatisticians spelling out MAYO!
February 11, 2025 at 9:00 PM
Onsite retreat today - my fellow biostatisticians spelling out MAYO!
The fearless leaders of #SISAQOL: Anders Ingelgaard & Madeline Pe — thank you for your vision and work to enhance PRO statistical analysis for everyone!
February 4, 2025 at 2:50 PM
The fearless leaders of #SISAQOL: Anders Ingelgaard & Madeline Pe — thank you for your vision and work to enhance PRO statistical analysis for everyone!
Stakeholder panel at #SISAQOL. Interesting discussion about whether collection of PROs post-progression is feasible, how to make PROs less burdensome, & where to place PROs in the hierarchy of clinical trial endpoints. Universal agreement that SISAQOL moves the field forward!
February 4, 2025 at 2:36 PM
Stakeholder panel at #SISAQOL. Interesting discussion about whether collection of PROs post-progression is feasible, how to make PROs less burdensome, & where to place PROs in the hierarchy of clinical trial endpoints. Universal agreement that SISAQOL moves the field forward!
Coming soon from #SISAQOL: guidebook, interactive table, glossary, patient material, and more! Will be posted on the SISAQOL website. www.sisaqol-imi.org
February 4, 2025 at 2:34 PM
Coming soon from #SISAQOL: guidebook, interactive table, glossary, patient material, and more! Will be posted on the SISAQOL website. www.sisaqol-imi.org
Coming soon from #SISAQOL for patient advocates & patient research partners: checklist for reviewing PRO measures in protocols, and checklist for reviewing visualizations in cancer clinical trials.
February 4, 2025 at 11:19 AM
Coming soon from #SISAQOL for patient advocates & patient research partners: checklist for reviewing PRO measures in protocols, and checklist for reviewing visualizations in cancer clinical trials.
Harmonized terms to replace the vague term “MID” from #SISAQOL! Need to be clear about whether you are talking about within-patient change (eg, responder analysis) or three group-level options (mean comparisons within or between groups - see slides).
February 4, 2025 at 10:14 AM
Harmonized terms to replace the vague term “MID” from #SISAQOL! Need to be clear about whether you are talking about within-patient change (eg, responder analysis) or three group-level options (mean comparisons within or between groups - see slides).
This #SISAQOL #dataviz recommendation gets a dedicated post. While I agree in general with including sample size, missing data, & incurrent event information on all graphs for clarity, three lines of text per arm may be infeasible for multi-arm trials and may be more readable in a standalone table.
February 4, 2025 at 10:13 AM
Excited that #SISAQOL included recommendations about #dataviz for #patientreportedoutcomes! Graphs vary by audience consistent with prior literature. Include p-values for preplanned tests only, and use consistent y-axis scaling throughout your paper.
February 4, 2025 at 10:11 AM
Excited that #SISAQOL included recommendations about #dataviz for #patientreportedoutcomes! Graphs vary by audience consistent with prior literature. Include p-values for preplanned tests only, and use consistent y-axis scaling throughout your paper.
Next #SISAQOL turns to #patientreportedoutcomes in single-arm trials. PRO objectives should be clearly defined & can be descriptive (more common) or comparative to historical control data. Important to consider missing data & incurrent events as in randomized trials.
February 4, 2025 at 9:21 AM
Next #SISAQOL turns to #patientreportedoutcomes in single-arm trials. PRO objectives should be clearly defined & can be descriptive (more common) or comparative to historical control data. Important to consider missing data & incurrent events as in randomized trials.
Next #SISAQOL highlights involve missing data. Need to separate missing data from intercurrent events, and recommendations reinforce using “completion rate” & “available data rate” - quit using “compliance rate” in your papers! Finally, avoid biased missing data approaches.
February 4, 2025 at 9:19 AM
Next #SISAQOL highlights involve missing data. Need to separate missing data from intercurrent events, and recommendations reinforce using “completion rate” & “available data rate” - quit using “compliance rate” in your papers! Finally, avoid biased missing data approaches.
Diving into #SISAQOL recommendations. First highlights involve handling death or other intercurrent events. Basically there is no standard approach but need to be clear in the approach that you are using. Some new language here that many folks might not be familiar with…
February 4, 2025 at 9:18 AM
Diving into #SISAQOL recommendations. First highlights involve handling death or other intercurrent events. Basically there is no standard approach but need to be clear in the approach that you are using. Some new language here that many folks might not be familiar with…
Excited for a full day of new #SISAQOL recommendations for the statistical analysis of #patientreportedoutcomes in cancer clinical trials!
February 4, 2025 at 8:32 AM
Excited for a full day of new #SISAQOL recommendations for the statistical analysis of #patientreportedoutcomes in cancer clinical trials!
Please select the one emoji that best represents your feeling towards our research paper developing emoji scales for assessing #patientreportedoutcomes: 😩 ☹️ 😐 🙂 😄
Can an emoji scale be used to report a patient's health status and feelings to health care providers? Find out by reading our latest JCO CCI article: ascopubs.org/doi/full/10.... @ascocancer.bsky.social @biostatgirl.bsky.social
ASCO Publications
ascopubs.org
January 8, 2025 at 6:13 PM
Please select the one emoji that best represents your feeling towards our research paper developing emoji scales for assessing #patientreportedoutcomes: 😩 ☹️ 😐 🙂 😄
Excited to see #PROCTCAE and #GP5 in the inavolisib label! Recurring points in the FDA discussion about needing dose optimization in early drug development to lower doses, maintain efficacy, and improve tolerability. Also comments about needing enrollment of diverse patients. #SABCS24
December 10, 2024 at 7:21 PM